One-Year Exploratory Study to Evaluate the Safety of Partial Replacement of CNI With Chronic Administration of Simulect in de Novo Normal-Risk Kidney Transplant Recipients Treated With MPA

Trial Profile

One-Year Exploratory Study to Evaluate the Safety of Partial Replacement of CNI With Chronic Administration of Simulect in de Novo Normal-Risk Kidney Transplant Recipients Treated With MPA

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 13 Feb 2015

At a glance

  • Drugs Basiliximab (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Aug 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 06 Jul 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top